

**AMENDMENTS TO THE CLAIMS:**

Please amend claims 2 and 22, as shown below.

This listing of claims will replace all prior versions and listings of claims in the Application:

**Claim 1 (cancelled).**

**Claim 2 (currently amended):** The pharmaceutical composition according to claim 22, wherein said compound is selected from the group consisting of:

2,2' -[(3-Propylphenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2' -[(3-Dimethylamino)phenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2' -[(3-(Methylethyl)phenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2' -[(3-Methylphenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2' -[(3-Methoxyphenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2' -[(3-Ethoxyphenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2' -[(3-Chlorophenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

~~2,2' -[(3-Bromophenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;~~

2,2' -[[3-(2-Ethylbutyl)phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)  
imino]methyl]] phenol;

2,2' -[[3-Cyclohexyl)phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)  
imino]methyl]]phenol;

2,2' -[[3-Butylphenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1 -  
yl)imino]methyl]]phenol;

2,2' -[[3-Fluorophenyl)methylene]bis[4- [[[(5-methyl-1H-tetrazol-1-yl)  
imino]methyl]]phenol;

2,2' -[[3-Pentylphenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)  
imino]methyl]]phenol;

2,2' -[[3-(1-Methylpropyl)phenyl]methylene]bis[ 4-[[[(5-methyl-1H-tetrazol-1-yl)  
imino]methyl]]phenol;

2,2' -[[3-(2-Methylpropyl)phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1 -  
yl)imino]methyl]]phenol;

2,2' -[[3-Methoxyethyl)phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)  
imino]methyl]]phenol;

2,2' -[[3-Ethylphenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)  
imino]methyl]]phenol;

2,2' -[[[3-Ethyl(methylethyl)amino]phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-  
yl)imino]methyl]]phenol;

2,2' -[[3-Ethylpropylamino)phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)  
imino]methyl]]phenol;

2,2' -[[3-Diethylamino)phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)

imino]methyl]]phenol;

2,2'-[[[(3-Butylethylamino)phenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)

imino]methyl]]phenol;

2,2'-[[[(3-Methylamino)phenyl)methylene]bis [4-[[[(5-methyl-1H-tetrazol-1-yl)

imino]methyl]]phenol;

3-[[[Bis[[5-(5-methyl-1H-tetrazol-1-yl)imino]methy]-2-hydroxyphenyl)methylene]-N,N-diethylbenzenesulfonamide;

2,2' -[[[3-(2-Dimethylaminoethoxy)phenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]] phenol;

N-[[[3-[Bis[[5-(5-methyl-1H-tetrazol-1-yl)imino]methyl]-2-hydroxylphenyl)methylene]phenyl]-2,2-dimethylpropanamide;

N-[[[3-[Bis[[5-(5-methyl-1H-tetrazol-1-yl)imino]methyl]-2-hydroxylphenyl)methylene]phenyl]butanesulfonamide;

2,2'-[(3-Nitrophenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]] phenol;

2,2'-[(3-Methylthiophenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2' -[(3-Methylsulfinylphenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2' '-[(3-Methylsulfonylphenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

3-[[[Bis [[5-(5-methyl-1H-tetrazol-1-yl)imino]methyl]-2-hydroxyphenyl)methylene]-N,N-dimethylbenzenesulfonamide;

2,2' -[(3-Propylaminophenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2' -[[3-[2-(Diethylaminopropoxy)phenyl]methylene ]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]] phenol;

N-[[3-[Bis[[5-(5-methyl-1H-tetrazol-1-yl)imino]methyl]-2-hydroxylphenyl]methylene]phenyl] acetamide;

N-[[3-[Bis[[5-(5-methyl-1H-tetrazol-1-yl)imino]methyl]-2-hydroxylphenyl]methylene]phenyl]-N-propylacetamide;

N-[[3-[Bis[[5-(5-methyl-1H-tetrazol-1-yl)imino]methyl]-2-hydroxylphenyl]methylene]phenyl]-N-(methylethyl)acetamide;

N-[[3-[Bis[[5-(5-methyl-1H-tetrazol-1-yl)imino]methyl]-2-hydroxylphenyl]methylene]phenyl]-3-methyl-N-propylbutanamide;

N-[[3-[Bis[[5-(5-methyl-1H-tetrazol-1-yl)imino]methyl]-2-hydroxylphenyl]methylene]phenyl]-3-methyl-N-(methylethyl)butanamide;

N-[[3-[Bis[[5-(5-methyl-1H-tetrazol-1-yl)imino]methyl]-2-hydroxylphenyl]methylene]phenyl]-3-methyl-N-methylbutanamide;

N-[[3-[Bis[[5-(5-methyl-1H-tetrazol-1-yl)imino]methyl]-2-hydroxylphenyl]methylene]phenyl]-N-ethylacetamide;

N-[[3-[Bis[[5-(5-methyl-1H-tetrazol-1-yl)imino]methyl]-2-hydroxylphenyl]methylene]phenyl]propane sulfonamide; and

2,2' -[[3-Methyl(methylethyl)aminophenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol.

**Claim 3 (previously presented):** The pharmaceutical composition according to claim 22, wherein said compound is selected from the group consisting of:

2,2'-[(3-Propylphenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol,

2,2'-[[[(3-Dimethylamino)phenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol,

2,2' -[[[3-(Methylethyl)phenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol,

2,2' -[[[(3-Methoxyethyl)phenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol,

2,2' -[[[3-Ethyl(methylethyl)amino]phenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol, and

2,2'-[[[(3-Diethylamino)phenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol.

**Claim 4 (previously presented):** The pharmaceutical composition according to claim 22, wherein the compound is 2,2'-[(3-Propylphenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol.

**Claim 5 (previously presented):** The pharmaceutical composition according to claim 22, wherein the compound is 2,2'-[[[(3-Dimethylamino)phenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol.

**Claim 6 (previously presented):** The pharmaceutical composition according to claim 22, when the compound is 2,2'-[[[3-(Methyl)phenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol.

**HAYES SOLOWAY P.C.**  
3450 E. SUNRISE DRIVE,  
SUITE 140  
TUCSON, AZ 85718  
TEL. 520.882.7623  
FAX. 520.882.7643

175 CANAL STREET  
MANCHESTER, NH 03101  
TEL. 603.668.1400  
FAX. 603.668.8567

**Claim 7 (previously presented):** The pharmaceutical composition according to claim 22, when the compound is 2,2'-[[[(3-Methoxyethyl)phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]]phenol.

**Claim 8 (previously presented):** The pharmaceutical composition according to claim 22, when the compound is 2,2'-[[[(3-Ethyl(methylethyl)amino)phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]]phenol.

**Claim 9 (previously presented):** The pharmaceutical composition according to claim 22, when the compound is 2,2'-[[[(3-Diethylamino)phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]]phenol.


**Claim 10 (previously presented):** The pharmaceutical composition according to claim 22, when the compound is 2,2'-[[[(3-Ethylpropylamino)phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]]phenol.

**Claim 11 (cancelled).**

**Claim 12 (previously presented):** The pharmaceutical composition according to claim 22, further comprising at least one supplemental active agent selected from the group consisting of interferon, ribavirin an immunomodulator, an immunoglobulin, an anti-inflammatory agent, an antibiotic, an anti-viral and an anti-infective

**Claims 13-21 (cancelled).**

**Claim 22 (currently amended):** A pharmaceutical composition for treating pneumovirus infection comprising a compound having the formula:



wherein:

R<sub>1</sub> represents a radical selected from the group consisting of alkoxy, alkoxyalkyl, ~~halogen~~, nitro, carboxy, carboxyalkyl, carbalkoxy, carbalkoxyalkyl, carboxamide, carboxamidoalkyl, alkyl, cycloalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, sulfonamide, amidino, ~~eyano~~, amino, ~~amide~~, alkylamino, dialkylamino, alkylaminoalkyl, and alkoxy monosubstituted with a substituent selected from the group consisting of carboxy, amino, alkylamino and dialkylamino; and pharmaceutically acceptable salts of said compound in an amount effective to attenuate infectivity of said virus, and a pharmaceutically effective carrier medium, wherein said carrier medium comprises about 85% ethanol, about 10% propylene glycol and about 5% water.

**Claim 23 (previously presented):** The pharmaceutical composition according to claim 22, wherein said pharmaceutical composition comprises less than 5% water.

**Claims 24-35 (cancelled).**

HAYES SOLOWAY P.C.  
3450 E. SUNRISE DRIVE,  
SUITE 140  
TUCSON, AZ 85718  
TEL. 520.882.7623  
FAX. 520.882.7643

175 CANAL STREET  
MANCHESTER, NH 03101  
TEL. 603.668.1400  
FAX. 603.668.8567